# Study to Evaluate HT-4253 in Healthy Subjects

> **NCT06537817** · PHASE1 · COMPLETED · sponsor: **Halia Therapeutics, Inc.** · enrollment: 80 (actual)

## Conditions studied

- Normal Healthy Subjects

## Interventions

- **DRUG:** HT-4253
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06537817
- **Lead sponsor:** Halia Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-17
- **Primary completion:** 2025-05-12
- **Final completion:** 2025-05-12
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06537817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06537817, "Study to Evaluate HT-4253 in Healthy Subjects". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06537817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*